Core Viewpoint - Huajian Medical (01931) has seen a significant stock increase of over 13% following the announcement of a conditional agreement to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of shares. This acquisition aims to enhance capital synergy and establish an innovative cooperative network to support the globalization of Chinese assets [1][2]. Group 1 - Huajian Medical's stock rose by 13.31% to HKD 10.98, with a trading volume of HKD 45.6534 million [1]. - The acquisition of Guofu Quantum will make Huajian Medical the major shareholder, aiming to strengthen capital collaboration and broaden institutional cooperation [1]. - The company has launched several strategic initiatives since late July, including the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2]. Group 2 - Huajian Medical's U.S. subsidiary is pursuing a stablecoin license, and the company has partnered with BGI's Huada Gongying to establish the world's first "innovative drug intellectual property tokenization fund" [2]. - The company announced the initiation of a "global enhanced Ethereum (ETH) treasury" strategy and completed a compliant purchase of HKD 149 million in ETH [2]. - Huajian Medical is seeking shareholder approval for a HKD 3 billion ETH purchase authorization to support the ecosystem construction of the medical innovative drug RWA trading platform [2].
港股异动 | 华检医疗(01931)再涨超13% 拟斥超31亿港元收购国富量子20.31股份 持续推动RWA生态落地